Three insights:
1. The double-blinded trial is evaluating the efficacy of IDCT at two dosage levels in participants with single-level symptomatic lumbar degenerative disc disease.
2. IDCT is an allogeneic, non-invasive cell therapy that is injected into the painful disc percutaneously.
3. It uses biomedically engineered progenitor cells — known as discogenic cells — that are derived from intervertebral disc tissue to look for a regenerative solution to degenerative disc disease.
More articles on biologics:
NanoFUSE Biologics to crack Panama market — 3 things to know
Orthofix names DePuy, Medtronic, Biomet veteran the next CEO
Camber Spine delves into biologics with portfolio expansion
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.